WAKEFIELD, MA, April 29 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp , a developer and manufacturer of medical products that fight infection and inflammation, will release first quarter 2008 financial results on Tuesday, May 6, 2008. The company will host a conference call that day at 4:30 PM ET to discuss the financial results for the quarter.
In addition to the standard disclosure over wire services, a news release and financial statements will be posted on the NUCRYST website.
About NUCRYST Pharmaceuticals
NUCRYST Pharmaceuticals develops, manufactures and commercializes medical products that fight infection and inflammation using its patented atomically disordered nanocrystalline silver technology. Smith & Nephew plc sell a range of advanced wound care products under their Acticoat(TM) trade mark. Acticoat(TM) products incorporate NUCRYST’s SILCRYST(TM) coatings and are sold in over 30 countries. NUCRYST is also developing pharmaceutical products to address medical conditions that are characterized by both infection and inflammation. The Company has developed its proprietary nanocrystalline silver in a powder form, referred to as NPI 32101 for use in medical devices and as an active pharmaceutical ingredient.
Acticoat(TM) is a trademark of Smith & Nephew plc
SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.
CONTACT: Gregory W. Gin, Lazar Partners, (212) 867-1762, info@nucryst.com
